Terkko Navigator / Seminars in Oncology

KRAS mutation in pancreatic cancer

Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans

Radiotherapy for locally advanced pancreatic ductal adenocarcinoma

Future directions in drug development in pancreatic cancer

Irreversible electroporation of locally advanced pancreatic cancer

Pancreatic ductal adenocarcinoma in the era of precision medicine

Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain

Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview

Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center

Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study

Cancer diagnosis in Brazil in the COVID-19 era

COVID 19 Pandemic Testing Time – Crisis or opportunity in disguise for India?

Rare SARS-CoV-2 antibody development in cancer patients

A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapy

A systematic review with in silico analysis on transcriptomic profile of gallbladder carcinoma

Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies

Homologous recombination repair deficiency as a therapeutic target in sarcoma

Combination therapy in metastatic renal cell carcinoma: Back to the future?

Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?

Preservation of fertility in female: Indications, available options, and current status in Saudi Arabia

Depression in women with a diagnosis of breast cancer. Prevalence of symptoms of depression in Peruvian women with early breast cancer and related sociodemographic factors

Landmark trials in the medical oncology management of early stage breast cancer

Management of ER positive metastatic breast cancer

Biographies of the authors

Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer

Management of early breast cancer in patients bearing germline BRCA mutations

Systemic therapy for metastatic HER2-positive breast cancer

Further Thoughts on Preclinical Animal Models for Cancer Prevention: When Is It Best to Start Treatment? What Are Potential Histopathologic Endpoints?